Vertex Pharmaceuticals has secured a reimbursement agreement with NHS England, granting eligible sickle cell disease (SCD) patients access to *CASGEVY® (exagamglogene autotemcel)*, a CRISPR/Cas9 gene-edited therapy. The agreement follows the National Institute for Health and Care Excellence's (NICE) positive guidance and builds on a prior agreement for transfusion-dependent beta thalassemia (TDT) patients. Vertex is also working with hospitals across England to establish authorized treatment centers. This milestone marks a significant advancement in treatment options for SCD patients, offering a potential one-time therapy to address the disease’s underlying cause. (*Vertex Pharmaceuticals*)